Product Information

TACLONEX 0.005%-0.064% SUSPENSION is a brand product labeled by LEO Pharma Inc., priced at $20.6968 per GM under NDC 50222050106. Its NADAC has been published 665 times since Nov 28, 2013.

FDA first approved this application on May 9, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the calcipotriene and betamethasone dipropionate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

TACLONEX 0.005%-0.064% SUSPENSION

calcipotriene and betamethasone dipropionate
$20.6968per GM
High Outlier

Strength

.5; 50 mg/g; ug/g

Manufacturer

LEO Pharma Inc.

NDC

50222050106

Classification

Brand

Dosage Form

SUSPENSION

Route

TOPICAL

Effective Date

11/19/2025

Approval Type

New Drug (NDA)

FDA Application

NDA022185

FDA Approved

5/9/2008

TE Code

AB

On Market Since

6/1/2008

Pharmacological Classes

Corticosteroid Hormone Receptor Agonists
Corticosteroid
Vitamin D Analog
Vitamin D

Price Statistics

The NADAC for TACLONEX 0.005%-0.064% SUSPENSION has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 106.5%. The table below summarizes its recorded NADAC range and movement.

Current price$20.6968 per GM
All-time high$20.8744 (Aug 14, 2024)
All-time low$10.0241 (Nov 28, 2013)
52-week high$20.6968
52-week low$20.6678
Median price$17.6982
Average price$16.7273
Largest weekly change+12.0% (Jan 13, 2016)
Weeks tracked665
Tracking sinceNov 28, 2013

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

+0.0%

3Y

+3.0%

5Y

+13.5%

All

+106.5%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 94% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of TACLONEX 0.005%-0.064% SUSPENSION?

The current National Average Drug Acquisition Cost (NADAC) for TACLONEX 0.005%-0.064% SUSPENSION, manufactured by LEO Pharma Inc., is $20.6968 per GM (NDC 50222050106), effective Aug 19, 2026.

How has the price of TACLONEX 0.005%-0.064% SUSPENSION changed over time?

Over the history we have for it, the NADAC for TACLONEX 0.005%-0.064% SUSPENSION has risen 106.5%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for TACLONEX 0.005%-0.064% SUSPENSION?

Since Nov 28, 2013, the NADAC for TACLONEX 0.005%-0.064% SUSPENSION has ranged from a low of $10.0241 (Nov 28, 2013) to a high of $20.8744 (Aug 14, 2024), with a median of $17.6982 per GM.

Are there cheaper alternatives to TACLONEX 0.005%-0.064% SUSPENSION?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CALCIPOTRIENE-BETAMETHASONE DP 0.005%-0.064% SUSPENSION, is $1.2133 per GM — about 94% below TACLONEX 0.005%-0.064% SUSPENSION.

Who manufactures TACLONEX 0.005%-0.064% SUSPENSION?

TACLONEX 0.005%-0.064% SUSPENSION (NDC 50222050106) is labeled by LEO Pharma Inc., and CMS classifies it as a brand product.